{"id":82993,"date":"2025-09-08T16:39:48","date_gmt":"2025-09-08T16:39:48","guid":{"rendered":"https:\/\/www.merckconnect.ca\/en\/?post_type=mhh-sticky-footer&#038;p=82993"},"modified":"2026-01-23T17:24:32","modified_gmt":"2026-01-23T17:24:32","slug":"keytruda-lenvima-sticky","status":"publish","type":"mhh-sticky-footer","link":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","title":{"rendered":"Keytruda Lenvima Sticky"},"content":{"rendered":"<div class=\"mhh-sticky-footer-panel mhh-sticky-footer-panel--aab265e3eee4ef27047cf09503cf4de3\">\n    <button class=\"mhh-sticky-footer-panel__expand-button\" \n            data-event-name=\"accordion_click\" \n            data-design-module=\"indication\"\n            data-design-category=\"accordion\"\n            data-design-label=\"expand\">\n                    <svg\n            xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n            fill=\"currentColor\"\n            viewBox=\"0 0 16 16\"\n            >\n            <path\n            d=\"M8 4a.5.5 0 0 1 .5.5v3h3a.5.5 0 0 1 0 1h-3v3a.5.5 0 0 1-1 0v-3h-3a.5.5 0 0 1 0-1h3v-3A.5.5 0 0 1 8 4z\"\/>\n            <\/svg>\n                <span>EXPAND<\/span>\n        <\/button>\n    <div class=\"mhh-sticky-footer-inner\">\n    \n\n<div style=\"height:12px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--right  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3f868247305d910abf844927a9b23190\"><a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/KEYTRUDA-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">KEYTRUDA\u00ae Product Monograph<\/a><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color has-object-object-font-size wp-elements-b91fa9920e74458bfb875b7bfe485690 mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e98bddc4ccdab3c121a492900695b84a\" style=\"background-color:#6cc04a\"><strong>KEYTRUDA\u00ae  IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n\n    <\/div>\n<\/div>\n\n\n<div class=\"mhh-sticky-footer-expanded-panel mhh-sticky-footer-expanded-panel--f50bf3832e14000c7dbe72662d79e6cc \" dir=\"ltr\">\n    <div class=\"mhh-sticky-footer-expanded-panel__inner\">\n        <div class=\"mhh-sticky-footer-expanded-panel__close-button-wrapper\">\n            <button class=\"mhh-sticky-footer-expanded-panel__close-button\">\n                        <svg\n                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                fill=\"currentColor\"\n                viewBox=\"0 0 16 16\"\n            >\n                <path\n                d=\"M4.646 4.646a.5.5 0 0 1 .708 0L8 7.293l2.646-2.647a.5.5 0 0 1 .708.708L8.707 8l2.647 2.646a.5.5 0 0 1-.708.708L8 8.707l-2.646 2.647a.5.5 0 0 1-.708-.708L7.293 8 4.646 5.354a.5.5 0 0 1 0-.708z\"\/>\n            <\/svg>\n                                    <\/button>\n        <\/div>\n        <div class=\"mhh-sticky-footer-expanded-panel__body\">\n            \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color has-object-object-font-size wp-elements-b91fa9920e74458bfb875b7bfe485690 mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e98bddc4ccdab3c121a492900695b84a\" style=\"background-color:#6cc04a\"><strong>KEYTRUDA\u00ae  IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--9358ef2a7858a88a3ee2058dfd5d50ff mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--ca92eac8c9d2b19a05ed0a9c4dc76642 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--2a7e4b0bf0c9fe1be910b962fd89250c\">KEYTRUDA\u00ae has been issued marketing authorization for:<\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--346f06d77a622c6ac71488e9fbf1f9de mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic RCC in combination with lenvatinib with no prior systemic therapy for metastatic RCC    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Treatment of adult patients with advanced endometrial carcinoma, in combination with lenvatinib, that is not MSI-H or dMMR, who have disease progression following prior platinum-based systemic therapy and are not candidates for curative surgery or radiation    <\/li>\n\n<\/ul>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--0908490cd10dc3e9d01f516a34d02ddf\"><strong><u>Clinical use:<\/u><\/strong><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e1adbc1722b0fddecc8dd1a06dc88a4a\">The safety and efficacy of KEYTRUDA\u00ae has not been established for pediatric patients with conditions other than melanoma (Stage IIB, IIC, or III), relapsed or refractory cHL, or relapsed or refractory PMBCL, or unresectable or metastatic MSI-H or dMMR solid tumours.<br><br>Geriatrics (\u226565 years of age): No overall differences in safety or efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years) for KEYTRUDA\u00ae monotherapy . No overall differences in efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years) for KEYTRUDA\u00ae combination therapy. Limited safety and efficacy information is available for KEYTRUDA\u00ae in cHL \u2265 65 years of age (n=20).<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--066a6593bce6b4908725191dedb684ee\"><strong><u>Relevant warnings and precautions<\/u>:<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--ee5d38289654daab17eb1893210e5b22 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Immune-mediated adverse reactions, including severe and fatal cases:    <\/li>\n\n<\/ul>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--cc7c766c2e96b675fd3ecb9575e1aa7d mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pneumonitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Colitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Hepatitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Nephritis and renal dysfunction    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Endocrinopathies including adrenal insufficiency, hypophysitis, type 1 diabetes mellitus, and thyroid disorders    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis    <\/li>\n\n<\/ul>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--d8000bb843b3f3a46bb13711ea328780 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Other immune-mediated adverse events including uveitis, arthritis, myositis, encephalitis, sarcoidosis, myasthenic syndrome\/myasthenia gravis, vasculitis, Guillain-Barr\u00e9 syndrome,<br>hemolytic anemia, pancreatitis, myelitis, hypoparathyroidism, gastritis, pericarditis, myocarditis, sclerosing cholangitis, aplastic anemia, and exocrine pancreatic insufficiency    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Solid organ transplant rejection    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Use in combination with axitinib for RCC    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Allogeneic stem cell transplant after and before treatment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe infusion-related reactions    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Teratogenic toxicity    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Women of childbearing potential should use highly effective contraception and take active measures to avoid pregnancy during treatment and for at least 4 months after the last dose    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Advise women not to breastfeed during treatment and for at least 4 months after the last dose    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Patients with hepatic impairment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Renal impairment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Driving and operating machinery    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Monitoring requirements    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pediatrics    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Geriatrics    <\/li>\n\n<\/ul>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--92d82ce5f877b2ef2745e6cee51c4a33\"><strong><span style=\"text-decoration: underline\"><strong><strong><u>For more information:<\/u><\/strong><\/strong><\/span><\/strong><br><br>Consult the KEYTRUDA\u00ae <a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/KEYTRUDA-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Product Monograph<\/a> for important information regarding adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling us at 1-800-567-2594 or by email at medinfocanada@merck.com.<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f279dcf193b60e355df99dd9cbefba61\"><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 dir=\"ltr\" lang=\"en-US\" class=\"wp-block-heading  has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-object-object-font-size mhh-mcn-v1-heading--center mhh-mcn-v1-heading mhh-mcn-v1-heading--5dff8bf2b081c6e00e2956bf48fec8b2\" style=\"background-color:#931d5e\"><strong>LENVIMA\u00ae IMPORTANT SAFETY INFORMATION<\/strong><\/h3>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--287884ffbfaaa52a4f20ac8f44aa5ef4\">LENVIMA\u00ae (lenvatinib capsules) is indicated:<\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--b8a09520577fb3688dfbf9c90f7f9c6b mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with pembrolizumab for the treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic RCC with no prior systemic therapy for metastatic RCC    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with pembrolizumab for the treatment of adult patients with advanced EC that is not MSI-H or dMMR, who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation    <\/li>\n\n<\/ul>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--baba63e95ba25ef2324944aa9d5c772b\"><strong><u>Clinical use<\/u>:<\/strong><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--4fab106bd78997b99b1cda5020a1410e\">The safety and efficacy of LENVIMA\u00ae have not been established in patients &lt;18 years of age.<br>In patients \u226565 years of age, adverse events Grade 3 or higher and discontinuations were higher than in patients &lt;65 years of age.<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9146dd50461a5fc139d248f834b2141d\"><strong><span style=\"text-decoration: underline\">Most serious warnings &amp; precautions<\/span>:<\/strong><br><br><strong>Hypertension and its complications, including fatal artery dissection<br><\/strong><br><strong>Cardiac failure, including fatal cases <br><\/strong><br><strong>Arterial thromboembolism (ATE), including fatal cases<\/strong><br><br><strong>Gastrointestinal perforation and fistula formation  <\/strong><br><br><strong>Hepatic\/biliary\/pancreatic: <\/strong>Hepatotoxicity\/hepatic failure, including fatal cases<br><br><strong>Renal:<\/strong> Renal failure and impairment, including fatal cases<br><br><strong>Hematologic: <\/strong>Hemorrhage, including fatal cases<br><br><strong>Neurologic: <\/strong>Posterior reversible encephalopathy syndrome (PRES)<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--285a41c9e894f5e58a883d5f772b750f\"><strong><u>Other relevant warnings and precautions:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--4f872a22760e43bd9255c8a566917460 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Prior anticancer treatments    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    QT interval prolongation; correct electrolyte abnormalities in all patients. Avoid use with electrolyte-disrupting drugs    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Hypocalcemia    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Impairment of thyroid stimulating hormone suppression\/thyroid dysfunction    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Diarrhea: Initiate prompt medical management    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Osteonecrosis of the jaw (ONJ): Consider a dental examination and preventative dentistry prior to initiating LENVIMA\u00ae. If possible, avoid invasive dental procedures. Caution is advised with agents associated with ONJ, such as bisphosphonates and denosumab    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Wound healing complications    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Proteinuria    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Fertility    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Men and women of reproductive potential should use contraception    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pregnancy: LENVIMA\u00ae should not be used during pregnancy unless necessary and based on a benefit\/risk assessment of the mother and fetus    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Breastfeeding: LENVIMA\u00ae should not be used during breastfeeding    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Not recommended for patients with end-stage renal disease    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Monitoring and laboratory tests    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    When  LENVIMA\u00ae is used in combination with pembrolizumab, see the pembrolizumab Product Monograph    <\/li>\n\n<\/ul>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e78d0b029710f94a3e5458f003eb934a\"><strong><u>For more information:<\/u><\/strong><br><br>Please consult the LENVIMA\u00ae <a href=\"https:\/\/ca.eisai.com\/-\/media\/Files\/CanadaEisai\/LENVIMA-Product-Monograph-EN.pdf?hash=f43eb602-ffb4-469b-910b-6253e91084bc\" target=\"_blank\" rel=\"noreferrer noopener\">Product Monograph<\/a> for important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed in this piece. The Product Monograph is also available by calling Eisai Limited at 1-877-873-4724.<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a5467bc61c227975fced7582011b42ab\">cHL=classical Hodgkin lymphoma; dMMR=mismatch repair deficiency; MSI-H=microsatellite instability high; PMBCL=primary mediastinal large B-cell lymphoma; RCC=renal cell carcinoma.&nbsp;<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e689839e43ffebfa6f7650188966bae9\"><br><\/p>\n\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<div class=\"mhh-sticky-footer-safety-content\">\n    <\/div>\n","protected":false},"template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"0","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"promomats_ca_generated_at":0,"promomats_ca_screen_sizes":["Desktop","Mobile"],"footnotes":""},"mh-depends-on":[],"class_list":["post-82993","mhh-sticky-footer","type-mhh-sticky-footer","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Keytruda Lenvima Sticky | Merck Connect Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keytruda Lenvima Sticky | Merck Connect Canada\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck Connect Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T17:24:32+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\",\"name\":\"Keytruda Lenvima Sticky | Merck Connect Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\"},\"datePublished\":\"2025-09-08T16:39:48+00:00\",\"dateModified\":\"2026-01-23T17:24:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.merckconnect.ca\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keytruda Lenvima Sticky\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"name\":\"Merck Connect Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\",\"name\":\"Merck Connect Canada\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"contentUrl\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"width\":1284,\"height\":331,\"caption\":\"Merck Connect Canada\"},\"image\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Keytruda Lenvima Sticky | Merck Connect Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","og_locale":"en_US","og_type":"article","og_title":"Keytruda Lenvima Sticky | Merck Connect Canada","og_url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","og_site_name":"Merck Connect Canada","article_modified_time":"2026-01-23T17:24:32+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/","name":"Keytruda Lenvima Sticky | Merck Connect Canada","isPartOf":{"@id":"https:\/\/www.merckconnect.ca\/en\/#website"},"datePublished":"2025-09-08T16:39:48+00:00","dateModified":"2026-01-23T17:24:32+00:00","breadcrumb":{"@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/keytruda-lenvima-sticky\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Keytruda Lenvima Sticky"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.ca\/en\/#website","url":"https:\/\/www.merckconnect.ca\/en\/","name":"Merck Connect Canada","description":"","publisher":{"@id":"https:\/\/www.merckconnect.ca\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.merckconnect.ca\/en\/#organization","name":"Merck Connect Canada","url":"https:\/\/www.merckconnect.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","contentUrl":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","width":1284,"height":331,"caption":"Merck Connect Canada"},"image":{"@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/82993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer"}],"about":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/types\/mhh-sticky-footer"}],"version-history":[{"count":6,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/82993\/revisions"}],"predecessor-version":[{"id":84571,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/82993\/revisions\/84571"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/media?parent=82993"}],"wp:term":[{"taxonomy":"mh-depends-on","embeddable":true,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mh-depends-on?post=82993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}